Jazz Pharmaceuticals has agreed to acquire privately held Actio Biosciences in a transaction designed to deepen its presence in rare and severe epilepsies and add a promising precision medicine to its development pipeline. Under the definitive merger agreement announced on August 10, 2026, Jazz will pay Actio shareholders $820 million upfront, with up to an additional $500 million available through potential regulatory approval and sales milestones. The acquisition centers on ABS-1230, Actio’s clinical-stage small molecule therapy targeting KCNT1-related epilepsy, a rare genetic disorder for which no U.S. Food and Drug Administration-approved treatment is currently available.
Strategic Expansion in Rare Epilepsy
The transaction builds on Jazz Pharmaceuticals’ existing epilepsy business, including its Epidiolex franchise, while giving the company access to a targeted therapy aimed at a highly underserved patient population. Jazz President and CEO Renee Gala described the addition of ABS-1230 as a strategic expansion of the company’s rare epilepsy portfolio that complements its development and commercialization capabilities in serious neurological diseases. Jazz also sees potential to explore ABS-1230 in additional genetic epilepsy indications beyond its current lead program, broadening the longer-term opportunity associated with the asset.
ABS-1230 Targets a Genetic Driver
ABS-1230 is designed as a potent, selective, and orally available inhibitor of the KCNT1 ion channel, addressing a genetic mechanism associated with severe forms of epilepsy. Actio reported that preclinical work showed activity across all evaluable pathogenic KCNT1 mutations, while an early proof-of-concept study in children with KCNT1-related epilepsy produced meaningful reductions in seizures. The candidate is currently being evaluated in the Phase 1b/2a KYRON trial, which is intended to serve as a registrational study supporting a future U.S. new drug application if the program generates sufficient clinical evidence.
Addressing a Severe Unmet Need
KCNT1-related epilepsy is a rare developmental and epileptic encephalopathy estimated by the companies to affect about 2,500 people in the United States, with many patients experiencing treatment-resistant seizures beginning in infancy. The companies said affected patients can experience dozens to hundreds of seizures each day, while early-onset disease may be associated with profound developmental impairment and, in some cases, death before adulthood. ABS-1230 has received FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations and has also been accepted into the agency’s Rare Disease Evidence Principles program, which is intended to support development of therapies for ultra-rare conditions.
Actio’s Remaining Pipeline to Be Spun Out
As part of the acquisition structure, Actio will spin out a new privately held company containing certain employees, management, and assets that are not part of Jazz’s purchase of ABS-1230. The new business will be backed by Actio’s existing investors, while Jazz will receive a minority interest and certain related rights, preserving a connection to the company’s continuing rare-disease research. Its pipeline will include ABS-0871, a clinical-stage TRPV4 inhibitor being developed for Charcot-Marie-Tooth disease type 2C, along with other early-stage programs focused on genetic neurological disorders.
The boards of Jazz Pharmaceuticals and Actio Biosciences have unanimously approved the transaction, which is expected to close by the fourth quarter of 2026 subject to customary closing requirements. Jazz plans to finance the acquisition using cash on hand together with existing financing facilities, while Actio CEO David Goldstein said Jazz’s development infrastructure and commercial reach made it a suitable partner to advance ABS-1230. If successfully completed, the deal will give Jazz a potentially first-in-class precision therapy for a rare epilepsy with no approved treatment, while allowing part of Actio’s broader pipeline to continue independently through the planned spinout.